Henrik S. Thomsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Henrik S. Thomsen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Sameh K. Morcos
Northern General Hospital, Sheffield Teaching, Hospitals NHS Foundation Trust
9 shared publicationsMembers of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR)
5 shared publicationsElizaveta Chabanova
Department of Diagnostic Radiology 54E2, Copenhagen University Hospital at Herlev, Herlev, Denmark
3 shared publications- Jakob Møllenbach Møller
Department of Radiology, Copenhagen University Hospital at Herlev Gentofte, Copenhagen, Denmark
2 shared publications Judith A. W. Webb
St. Bartholomew’s Hospital
2 shared publications- Vibeke Løgager
Radiological Department, Copenhagen University Hospital Herlev Gentofte, Herlev, Denmark
2 shared publications
Latest Publications
- 1 January 2007
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 17 (1) , 70-76
European Society of Urogenital Radiology guidelines on contrast media application
The present review covers the European Society of Urogenital Radiology guidelines for safe use of contrast media of importance for referring urologists. During the recent years contrast medium-induced nephropathy has become a hot topic. It is of importance to reduce its incidence. First of all, the patients at risk should be identified prior to the administration of a contrast medium, so that appropriate measures can be taken. Before intravenous administration of an iodinated agent but not before gadolinium-based and ultrasound agents, all patients should be questioned about the potential renal dysfunction at the time of referral, and only those who answer affirmative to at least one question should have their serum creatinine level determined. Before intraarterial injection, the serum creatinine should always be measured. In case of an abnormal level, another imaging procedure should be considered. If impossible, hydration should be instituted and administration of nephrotoxic drugs should be stopped. After administration, delayed reactions such as nephrogenic systemic fibrosis, thyreotoxicosis, skin rash, etc. may be seen. Interaction with isotope studies and biochemical analysis occurs too. The awareness regarding the potential adverse reactions due to contrast media and the necessary precautions to be taken are of utmost importance both for radiologists and referring physicians. This is the only way to reduce their incidence.
- 1 January 2007
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 17 (1) , 70-76
European Society of Urogenital Radiology guidelines on contrast media application
The present review covers the European Society of Urogenital Radiology guidelines for safe use of contrast media of importance for referring urologists. During the recent years contrast medium-induced nephropathy has become a hot topic. It is of importance to reduce its incidence. First of all, the patients at risk should be identified prior to the administration of a contrast medium, so that appropriate measures can be taken. Before intravenous administration of an iodinated agent but not before gadolinium-based and ultrasound agents, all patients should be questioned about the potential renal dysfunction at the time of referral, and only those who answer affirmative to at least one question should have their serum creatinine level determined. Before intraarterial injection, the serum creatinine should always be measured. In case of an abnormal level, another imaging procedure should be considered. If impossible, hydration should be instituted and administration of nephrotoxic drugs should be stopped. After administration, delayed reactions such as nephrogenic systemic fibrosis, thyreotoxicosis, skin rash, etc. may be seen. Interaction with isotope studies and biochemical analysis occurs too. The awareness regarding the potential adverse reactions due to contrast media and the necessary precautions to be taken are of utmost importance both for radiologists and referring physicians. This is the only way to reduce their incidence.
- 1 December 2006
- Published by Elsevier in European Journal of Radiology
- Vol. 60 (3) , 307-313
European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media
- 1 December 2006
- Published by Elsevier in European Journal of Radiology
- Vol. 60 (3) , 307-313
European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media
- Top Cited PapersOpen Access
- 24 October 2006
- Published by Springer Nature in European Radiology
- Vol. 16 (12) , 2619-2621
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
- 24 October 2006
- Published by Springer Nature in European Radiology
- Vol. 16 (12) , 2619-2621
Top Cited PapersOpen AccessNephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
- 9 June 2006
- Published by Springer Nature in European Radiology
- Vol. 17 (1) , 273-278
Initial clinical experience with oral manganese (CMC-001) for liver MR imaging
Recently, a new oral liver-specific manganese-based MR agent (CMC-001) has been introduced. This contrast medium is delivered to the liver in high concentrations in the portal vein and very low doses in the hepatic artery, as only small amounts of manganese enter the general circulation. It is taken up by the hepatocytes and excreted in the bile. Our initial experience with the new MR contrast medium in a variety of patients is reported. A total of 20 patients (11 males and 9 females) were studied with MR imaging 2 h after oral ingestion of the contrast agent. Sixteen patients were referred for evaluation of focal liver lesion(s), whereas in the remaining four patients, evaluation of the biliary tract was requested. In the 17 patients without biliary obstruction, there was an increased signal intensity of the liver parenchyma, whereas in the three patients with biliary obstruction, the uptake was delayed. There was excellent visualization of the biliary system on the T1-weighted images in the 16 patients without biliary obstruction referred for evaluation of a focal liver lesion. In seven patients, the uptake was patchy. In patients with focal liver lesions or biliary tract diseases, it is possible to increase the signal intensity of the liver parenchyma after the oral intake of CMC-001. In patients without biliary tract obstruction, the biliary system is easily visualized. Oral manganese seems to be useful in hepatobiliary MRI. Further research is strongly warranted.
- 9 June 2006
- Published by Springer Nature in European Radiology
- Vol. 17 (1) , 273-278
Initial clinical experience with oral manganese (CMC-001) for liver MR imaging
Recently, a new oral liver-specific manganese-based MR agent (CMC-001) has been introduced. This contrast medium is delivered to the liver in high concentrations in the portal vein and very low doses in the hepatic artery, as only small amounts of manganese enter the general circulation. It is taken up by the hepatocytes and excreted in the bile. Our initial experience with the new MR contrast medium in a variety of patients is reported. A total of 20 patients (11 males and 9 females) were studied with MR imaging 2 h after oral ingestion of the contrast agent. Sixteen patients were referred for evaluation of focal liver lesion(s), whereas in the remaining four patients, evaluation of the biliary tract was requested. In the 17 patients without biliary obstruction, there was an increased signal intensity of the liver parenchyma, whereas in the three patients with biliary obstruction, the uptake was delayed. There was excellent visualization of the biliary system on the T1-weighted images in the 16 patients without biliary obstruction referred for evaluation of a focal liver lesion. In seven patients, the uptake was patchy. In patients with focal liver lesions or biliary tract diseases, it is possible to increase the signal intensity of the liver parenchyma after the oral intake of CMC-001. In patients without biliary tract obstruction, the biliary system is easily visualized. Oral manganese seems to be useful in hepatobiliary MRI. Further research is strongly warranted.
- 4 May 2006
- Published by Springer Nature in European Radiology
- Vol. 16 (8) , 1835-1840
Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines
The interest in contrast-medium-induced nephropathy has increased considerably during the last few years. Various guidelines regarding identifying patients at risk and measures to reduce the incidence of this complication have been proposed. The aim of this review was to analyse whether there is some consistency amongst these guidelines. A Medline search for the keyword “contrast medium induced nephropathy” during the period from the beginning of 2003 through the end of September 2005 was carried out. Only papers in English were reviewed. Thirteen guidelines were identified. Inconsistency was observed regarding advise on the prophylactic use of drugs and the isoosmolar dimer to reduce the incidence of contrast-medium-induced nephropathy. Consistency was found in relation to the importance of hydration, cessation of intake of nephrotoxic drugs and administration of the lowest possible dose of contrast medium. No new consensus has been observed in comparison to the European Society for Urogenital Radiology (ESUR) guidelines, which were published in 1999.
- 4 May 2006
- Published by Springer Nature in European Radiology
- Vol. 16 (8) , 1835-1840
Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines
The interest in contrast-medium-induced nephropathy has increased considerably during the last few years. Various guidelines regarding identifying patients at risk and measures to reduce the incidence of this complication have been proposed. The aim of this review was to analyse whether there is some consistency amongst these guidelines. A Medline search for the keyword “contrast medium induced nephropathy” during the period from the beginning of 2003 through the end of September 2005 was carried out. Only papers in English were reviewed. Thirteen guidelines were identified. Inconsistency was observed regarding advise on the prophylactic use of drugs and the isoosmolar dimer to reduce the incidence of contrast-medium-induced nephropathy. Consistency was found in relation to the importance of hydration, cessation of intake of nephrotoxic drugs and administration of the lowest possible dose of contrast medium. No new consensus has been observed in comparison to the European Society for Urogenital Radiology (ESUR) guidelines, which were published in 1999.
- 30 January 2006
- Published by Springer Nature in Abdominal Radiology
- Vol. 31 (2) , 131-140
ESUR guidelines on contrast media
Since 1996 the Contrast Media Safety Committee of the European Society of Urogenital Radiology has released 15 guidelines regarding safety in relation to the use of radiographic, ultrasonographic, and magnetic resonance contrast media. The guidelines have been well received by the radiologic community in Europe and all over the world and comprise current standards for good practice at many institutions. The present report is an overview of the work accomplished by the European Society of Urogenital Radiology over the past 8 years. The committee has covered renal and nonrenal adverse events and other aspects of contrast media.
- 30 January 2006
- Published by Springer Nature in Abdominal Radiology
- Vol. 31 (2) , 131-140
ESUR guidelines on contrast media
Since 1996 the Contrast Media Safety Committee of the European Society of Urogenital Radiology has released 15 guidelines regarding safety in relation to the use of radiographic, ultrasonographic, and magnetic resonance contrast media. The guidelines have been well received by the radiologic community in Europe and all over the world and comprise current standards for good practice at many institutions. The present report is an overview of the work accomplished by the European Society of Urogenital Radiology over the past 8 years. The committee has covered renal and nonrenal adverse events and other aspects of contrast media.
- 5 December 2005
- Published by Springer Nature in Abdominal Radiology
- Vol. 31 (2) , 129-130
Guest Editor’s Introduction
- 5 December 2005
- Published by Springer Nature in Abdominal Radiology
- Vol. 31 (2) , 129-130
Guest Editor’s Introduction
- 31 May 2005
- Published by Elsevier in Academic Radiology
- Vol. 12 (5) , 652-657
Preliminary Experience With Contrast-enhanced MR Angiography in Patients With End-stage Renal Failure1
- 31 May 2005
- Published by Elsevier in Academic Radiology
- Vol. 12 (5) , 652-657
Preliminary Experience With Contrast-enhanced MR Angiography in Patients With End-stage Renal Failure1
- 1 May 2005
- Published by Elsevier in Academic Radiology
- Vol. 12 (5) , S21-S23
Oral manganese for liver and bile imaging
- 1 May 2005
- Published by Elsevier in Academic Radiology
- Vol. 12 (5) , S21-S23
Oral manganese for liver and bile imaging
- 1 February 2005
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (suppl_1) , i18-i22
How to avoid CIN: guidelines from the European Society of Urogenital Radiology
The Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) has looked at the effects of contrast media (CM) on the kidney including prevention of contrast medium-induced nephropathy (CIN) as well as at the possibility of identifying patients with increased risk of CIN nephropathy. This has resulted in five reports dealing with (i) serum creatinine; (ii) contrast medium-induced nephrotoxicity; (iii) haemodialysis and contrast media; (iv) use of gadolinium CM instead of iodinated CM; and (v) CM injection in diabetic patients receiving metformin. The review presents an overview of four of these five reports.
- 1 February 2005
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (suppl_1) , i18-i22
How to avoid CIN: guidelines from the European Society of Urogenital Radiology
The Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) has looked at the effects of contrast media (CM) on the kidney including prevention of contrast medium-induced nephropathy (CIN) as well as at the possibility of identifying patients with increased risk of CIN nephropathy. This has resulted in five reports dealing with (i) serum creatinine; (ii) contrast medium-induced nephrotoxicity; (iii) haemodialysis and contrast media; (iv) use of gadolinium CM instead of iodinated CM; and (v) CM injection in diabetic patients receiving metformin. The review presents an overview of four of these five reports.